Bruker Features New High Performance Mass Spectrometry Systems & Applications for the Detailed Analysis of Biotherapeutics at...

At the 58th ASMS conference, Bruker unveils a series of new products and application solutions targeted to improve the capabilities of researchers to develop biotherapeutics. As many biotherapeutics currently under development are protein or peptide based, Bruker has applied its extensive expertise in protein analysis to develop solutions for many common tasks in analyzing a protein or peptide based biotherapeutic including:

• Analysis of Truncations and Splice Variants
• Identification of Point Mutations
• Identification of Fusion Proteins
• Protein Glycoform Analysis
• Glycan Structure Identification
• PEGylation Analysis

At ASMS, Bruker will feature systems and applications built on the class leading Flex™ series of MALDI mass spectrometers for direct N- and C-terminal protein sequence analysis utilizing Bruker’s innovative top-down Edmass™ protein sequencing technology. This technique is often able to read dozens of amino acids from the important terminal residues of a protein, regardless of any protein modifications, and is superior in many aspects to traditional Edman sequencing. This application area is further enhanced by the launch of the new faster, highly efficient autoflex speed™ at ASMS designed to increase the productivity and capabilities of development operations.

In addition to the proven micrO-TOF™ and micrO-TOF-QII™ benchtop LCMS ESI-TOF systems, Bruker has applied its maXis™ UHR-TOF and amaZon ETD™ ion trap systems for the analysis of intact proteins and post translational modifications (PTMs). Several key technical presentations will highlight the powerful and unique capabilities of these systems to provide important information for the analysis of potential biotherapeutics. Utilization of the superior resolution (at least 40,000) and mass accuracy (